1. Home
  2. TGHL vs PLUR Comparison

TGHL vs PLUR Comparison

Compare TGHL & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The GrowHub Limited Class A Ordinary Shares

TGHL

The GrowHub Limited Class A Ordinary Shares

N/A

Current Price

$0.79

Market Cap

20.4M

Sector

Technology

ML Signal

N/A

Logo Pluri Inc.

PLUR

Pluri Inc.

HOLD

Current Price

$0.98

Market Cap

18.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGHL
PLUR
Founded
2020
2001
Country
Singapore
Israel
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.4M
18.5M
IPO Year
2024
2026

Fundamental Metrics

Financial Performance
Metric
TGHL
PLUR
Price
$0.79
$0.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 78.5K
12.9K
Earning Date
05-15-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.46
EPS
★ N/A
N/A
Revenue
N/A
★ $1,016,000.00
Revenue This Year
N/A
$902.46
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.27
$0.90
52 Week High
$2.48
$4.87

Technical Indicators

Market Signals
Indicator
TGHL
PLUR
Relative Strength Index (RSI) 46.46 29.34
Support Level $0.33 $0.90
Resistance Level $0.88 $1.85
Average True Range (ATR) 0.06 0.11
MACD -0.01 0.01
Stochastic Oscillator 58.99 32.26

Price Performance

Historical Comparison
TGHL
PLUR

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates as the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, the company has developed a multi-faceted approach to address industry challenges. Its business currently comprises two main divisions, which are the Traceability and Authenticity Solutions and Carbon Project Development.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: